PFIZER Aktie

 

Bei Valneva ist wieder ordentlich Bewegung drin. Gestern legte die Aktie um +6,45% auf 2,99 € zu und gehörte damit zu den stärksten Werten am französischen Aktienmarkt. Eine neue Unternehmensmeldung gab es am Mittwoch zwar nicht. Der Blick richtet sich aber immer stärker auf den Borreliose-Impfstoff mit Pfizer und bei den Analysten liegen einige Kursziele weit […] The post Valneva-Aktie: Analysten sehen über +150% Potenzial first appeared on sharedeals.de....

Patient investors who buy the stock may be rewarded over the long term....

– Typewriter's site-specific, non-viral technology uses only LNP-delivered RNA to insert whole genes into the genome, to create safer, re-dosable, durable genetic medicines – – Matthew Stanton, PhD, and Leanne Peiser, DPhil, appointed CEO and CSO, respectively; former Pfizer CSO Mikael......

Three blue-chip CFO swaps touched off double-digit stock rallies while Rivian's announcement landed with a thud. The difference comes down to one decision Rivian has yet to make....

Vier große Pharma-Namen, vier sehr verschiedene Bewertungen, und für Anleger entscheidet am Ende nicht die beste Bilanz, sondern der richtige Preis....

PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains....

Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously....

BRONX, N.Y.--(BUSINESS WIRE)--#Alzheimers--Oligomerix, Inc., a privately held, clinical-stage biotechnology company pioneering the development of novel small molecule therapeutics to address Alzheimer's disease (AD) and rare neurodegenerative diseases, today announced that Cara Cassino, M.D., has been appointed Interim President and Chief Executive Officer (CEO).Dr. Cassino has 25 years of clinical drug development and commercialization experience in both large pharma and biotech, with over 25 FDA/EMA drug approvals in a wide range of therapeutic areas. She has held senior leadership roles at Boehringer Ingelheim and Pfizer where she played an important role in the success of the blockbuster respiratory product Spiriva. She later joined Forest Laboratories (now part of Abbvie) as Senior Vice President of Clinical Development at a critical time in the company's evolution. She subsequently held C-suite positions in biotech, serving as Chief Medical Officer, EVP of Research & Development and Interim Co-CEO...

FDA Approves 3 New COVID-19 Vaccines Authored by Zachary Stieber via The Epoch Times, The Food and Drug Administration on Aug. 27 approved COVID-19 vaccines from Pfizer, Moderna, and Sanofi. A nurse prepares to give a COVID-19 vaccine to a child in Denver, Colo., on Nov. 3, 2021. (Michael Ciaglo/Getty Images) The new shots from Pfizer and Moderna use the messenger ribonucleic acid (mRNA) platform and target the XFG strain, a subvariant of the JN.1 variant. Regulators also cleared a COVID-19 vaccine shot from Sanofi that targets the XFG strain and does not use mRNA technology. The approval is for people aged 65 and older, as well as people aged 12 to 64 who have one or more underlying conditions such as obesity that officials say puts them at higher risk of severe COVID-19. Regulators have been approving updated COVID-19 vaccines for several years, in a bid to better match circulating strains. The previous versions of the vaccines were estimated to provide 58 percent protection against hospital...

Von Elias Schisgall DOW JONES--Die US-Gesundheitsbehörde FDA hat neue saisonale Covid-19-Impfstoffformulierungen der Hersteller Moderna, Pfizer und...

A single trial readout is reshuffling the mRNA vaccine trade this morning. BioNTech SE (NASDAQ:BNTX) stock is down 8% to $102.38 after the company terminated its Phase 2 colorectal cancer vaccine trial for futility, ending one of the highest-profile programs in its post-COVID oncology pivot. The read-across is hitting the platform peer group. Moderna (NASDAQ:MRNA) […]...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Pfizer's payout ratio is above 100%, but that's not the number you should probably be watching right now....

PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now....

Pfizer shares sit near a 52-week high after years of post-pandemic punishment, and now Wall Street analysts are quietly shifting their tone. Here is what the pipeline, the dividend, and the valuation math actually say about where PFE goes from here....

Pharma schlägt Öl: Eine Studie zu 29.078 US-Aktien zeigt, dass CVS Health im Zeitraum von 1928 bis 2023 eine höhere Gesamtrendite erzielte als Exxon. Die Hintergründe....

Pfizer is facing material patent expirations over the next two years, but that will be over by 2030....

Pfizer, Chevron, and AbbVie have already rewarded dividend investors with strong 2026 gains, but the bull case for 2027 pushes well beyond what Wall Street consensus currently projects, and the catalysts behind each target may surprise you....

Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far. Merck (NYSE:MRK) leads, Amgen (NASDAQ:AMGN) sits second, and Pfizer (NYSE:PFE) trails as a distant third. Merck stock is up 44% year to date (YTD) at $151.67. Meanwhile, Amgen stock is up 35% YTD at $440.84, which isn't bad at all ... Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?...